SURPASS-2
2021
Tirzepatide versus Semaglutide in Type 2 Diabetes
In 1,879 patients with T2DM on metformin, tirzepatide 5, 10 or 15 mg weekly reduced HbA1c and body weight more than semaglutide 1 mg weekly.
Result
Primary endpoint: Change in HbA1c at week 40
HbA1c −2.01/−2.24/−2.30 % vs −1.86 %; weight loss up to −11.2 kg vs −5.7 kg. All three doses superior to semaglutide (p<0.001).
- Subtopic
- Head-to-head vs semaglutide
- Design
- Open-label RCT, 40 weeks
- Relevance
- Supporting: context rather than must-know.
- Source
- Frías JP, et al. N Engl J Med. 2021;385(6):503-515.doi 10.1056/NEJMoa2107519
Discussion & critique
Established tirzepatide as the most potent glucose- and weight-lowering injectable for T2DM. SURPASS-CVOT (2025) later confirmed non-inferior CV outcomes vs dulaglutide.